Drug Discovery World

MARCH 26, 2024

For example, progress made in developing gene mutant-specific inhibitors, antibody-drug conjugates (ADC), or cellular therapies. OR: The presentations at ESMO TAT 2024 highlighted our advances in targeted and more personalised anti-tumour therapies. We were there to present the latest findings from our research.

RNA 64

RNA In-Vivo In-Vitro DNA 64

Drug Discovery World

OCTOBER 27, 2023

Organ-on-a-chip technology allows researchers to recreate the human tumour microenvironment in vitro, using human cells and capturing much of the complexity that characterises in vivo environments,” she says. But can organ-chips entirely replace other models? Not yet, according to Ewart. While the FDA’s Modernisation Act 2.0

Research 72

Research Gene Therapy In-Vivo In-Vitro 72

The Pharma Data

NOVEMBER 29, 2021

First Combination of Immunotherapy With Tyrosine Kinase Inhibitor Approved in Europe for Adult Patients With Advanced or Recurrent Endometrial Carcinoma With Disease Progression on or Following Prior Treatment With a Platinum-Containing Therapy in Any Setting and Who Are Not Candidates for Curative Surgery or Radiation.

In-Vitro 52

In-Vitro Containment Development Medicine 52

Drug Discovery World

AUGUST 3, 2022

These peptides typically contain up to 30 amino acids and can be cationic, amphipathic or both. This is a common reaction within peptide chemistry and it has been approved by regulatory authorities for various antibody-drug conjugates 4. Here, Bachem explores the science behind this approach. What are cell-penetrating peptides?

Bioavailability 52

Bioavailability In-Vivo RNA In-Vitro 52

pharmaphorum

NOVEMBER 2, 2021

Dr Laura Moriarty, senior marketing manager at Bio-Rad, looks at the impressive immuno-therapeutic potential of bispecific antibodies (bsAbs). Though their bispecific nature complicates large-scale production and purification workflows, with challenges such as antibody chain mispairing, bsAbs have come a long way since first developed.

Antibody 52

Antibody Immune Response Production Engineer 52

Drug Discovery World

FEBRUARY 1, 2024

This paid-for advertorial by Twist Bioscience appeared in the Therapeutic Antibodies Guide – DDW Volume 25 – Issue 1, Winter 2023/2024 Improving gene synthesis speed can reduce workflow times, saving you invaluable time, says Twist Bioscience. Traditionally, therapeutic antibody discovery is labour and resource intensive.

Antibody 64

Antibody Gene Protein Manufacturing 64

Camargo

NOVEMBER 29, 2021

Essentially, a biologic is a product that is produced from living organisms or that contains components of living organisms. Gene and cellular therapies. Monoclonal antibodies (mAbs). These products can be derived from humans, animals, or microorganisms with biotechnology. Blood and blood components. Allergenics. Somatic cells.

Development 180

Development Protein Production Hormones 180